Vice President, Development Innovations
Marcy Vallone joined Sarah Cannon in 2011 and serves as the vice president of Development Innovations, Sarah Cannon Research Institute (SCRI) full-service contract research organization (CRO). Vallone also oversees business development for SCRI, including alliance and strategic partnerships and business development activities for the research institute.
Vallone has nearly 20 years in clinical research experience primarily focused in early phase oncology. Prior to joining SCRI, Vallone conducted research for several pharmaceutical companies including Rigel Pharmaceuticals, Proteolix Inc. and Onyx Pharmaceuticals, an Amgen subsidiary where she served as a key member of the Kyprolis clinical development team. She graduated from Washington State University with a Bachelor of Science in Microbiology and has been a co-author on seven publications and 29 abstracts.